Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mouth Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Gemcitabine 8Cisplatin 8pembrolizumab 4durvalumab 4Specimen Handling 3Platinum 3Oxaliplatin 3Leucovorin 31,2-diaminocyclohexaneplatinum II citrate 3Taxes 2Nivolumab 2Magnetic Resonance Spectroscopy 2Folfox protocol 2Fluorouracil 2Biopsy 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1trastuzumab deruxtecan 1tivozanib 1peposertib 1guadecitabine 1fludarabine 1dehydroftorafur 1binimetinib 1avelumab 1atezolizumab 1Trastuzumab 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × peposertib × 90 days × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡